Equities
Health CareMedical Equipment and Services
  • Price (USD)82.77
  • Today's Change0.93 / 1.14%
  • Shares traded2.42m
  • 1 Year change-19.78%
  • Beta0.7276
Data delayed at least 15 minutes, as of Jan 27 2023 18:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Medtronic plc is a global healthcare technology company. The Company develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients. Its operating segments include Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Cardiovascular products include pacemakers, insertable cardiac monitors, and cardiac resynchronization therapy devices. Medical Surgical products include patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. Neuroscience products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems. Diabetes products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. It also provides PROPEL and SINUVA. The Company is focused on cardiac ablation portfolio.

  • Revenue in USD (TTM)30.81bn
  • Net income in USD4.32bn
  • Incorporated2014
  • Employees95.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Cathworks LtdAnnounced12 Jul 202212 Jul 2022Announced-6.95%--
Acutus Medical Inc-Left-Heart Access PortfolioDeal completed27 Apr 202227 Apr 2022Deal completed-22.49%87.00m
Data delayed at least 15 minutes, as of Jan 27 2023 18:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Baxter International Inc14.74bn-2.38bn23.27bn60.00k--4.20--1.58-4.72-4.7229.1010.980.61713.996.37245,666.70-9.906.03-11.667.2236.3841.58-16.0410.021.385.220.746538.319.524.7016.52-23.700.658916.53
Zimmer Biomet Holdings Inc7.15bn338.40m26.34bn19.50k78.102.1520.193.681.611.3234.0858.360.31550.93015.36366,805.101.501.031.691.1669.7971.164.743.311.057.200.318177.3511.560.4339400.007.13-1.880.00
GE HealthCare Technologies Inc17.99bn1.91bn31.42bn51.00k16.441.8712.141.754.214.2439.5737.08------352,784.30--------39.51--10.88--0.765397.250.0025--2.45--11.06------
Resmed Inc3.76bn809.47m34.01bn8.16k42.219.1035.319.045.505.5025.5825.520.65962.066.15461,185.7014.1913.1916.1015.5156.7157.3321.5118.671.8222.560.325140.4511.9311.6064.2617.8916.904.94
DexCom, Inc.2.79bn230.00m41.19bn6.30k199.2122.58107.9214.750.53540.53546.714.720.57732.875.11443,301.604.755.565.726.5065.9767.298.248.913.4312.920.52660.0027.0833.69-68.66--47.52--
Edwards Lifesciences Corp5.36bn1.46bn48.35bn15.70k33.677.7930.309.012.322.328.5410.040.63861.518.80341,643.3017.3715.9919.5618.9578.9375.1127.2023.633.00--0.08750.0019.2912.0482.5521.428.69--
Boston Scientific Corporation12.57bn597.00m66.39bn41.00k111.673.7638.405.280.41510.41518.7412.320.39382.317.10306,512.202.043.262.324.0068.8969.405.198.030.94566.770.32730.0019.927.23956.5223.201.75--
Becton Dickinson and Co18.87bn1.55bn70.60bn77.00k46.332.7918.713.745.385.8865.7289.220.35343.418.05245,064.903.062.213.542.5144.9245.788.666.550.62956.580.388586.56-1.369.312.058.456.00--
Intuitive Surgical, Inc.6.22bn1.32bn88.54bn9.79k68.617.9768.7414.233.653.6517.1931.450.46912.747.21--10.1412.8611.4614.3467.4468.3021.6127.144.13------8.9714.67-22.435.99----
Stryker Corporation17.95bn2.46bn95.51bn46.00k39.265.8027.775.326.436.4346.9543.510.51191.776.06390,173.907.016.738.047.9563.9565.5713.6913.161.19--0.436642.3919.218.6024.703.901.3911.20
Medtronic PLC30.81bn4.32bn108.86bn95.00k25.412.1015.463.533.223.2223.0139.000.33312.125.54324,294.804.705.085.355.7267.6268.4614.1015.451.4119.750.338362.615.211.3043.974.581.767.94
Abbott Laboratories43.65bn6.93bn193.66bn113.00k28.30--19.584.443.923.9224.74------------------56.1557.3015.8813.36--23.06----1.349.77-1.9530.77----
Data as of Jan 27 2023. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD

Institutional shareholders

31.16%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2022118.32m8.90%
BlackRock Fund Advisorsas of 30 Sep 202269.40m5.22%
SSgA Funds Management, Inc.as of 30 Sep 202258.99m4.44%
Massachusetts Financial Services Co.as of 30 Sep 202234.13m2.57%
Wellington Management Co. LLPas of 30 Sep 202231.10m2.34%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202228.78m2.16%
Geode Capital Management LLCas of 30 Sep 202226.80m2.02%
Managed Account Advisors LLCas of 30 Sep 202218.38m1.38%
JPMorgan Investment Management, Inc.as of 30 Sep 202214.71m1.11%
Lazard Asset Management LLCas of 30 Sep 202213.91m1.05%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.